Answers are grounded in this paper and cite their sources.
Staphylococcal eneterotoxin B (SEB) is known to form complexes with the major histocompatibility complex class II and T‐cell receptor in a manner that is quite different from the way natural ligands do, it bypasses the normal route of antigen processing by binding as an intact protein to the complex formed by the MHC class II receptor on the antigen‐presenting cell and the T cell receptor. Considerable amount of structural data is now available describing the molecular architecture for SEB and has identified the MHC class II and TCR recognition sites on the toxin molecule. An in silico three dimensional pharmacophore models for inhibition of the formation of SEB‐MHC‐II complex was created and used to identify potential inhibitors for SEB‐MHC‐II binding. These compounds are being tested using an in vitro toxin binding assay using Raji cells expressing MHC II. While carrying out the SEB binding assay, we identified several compounds demonstrating inhibition of the SEB binding to these cells. Binding assays carried out in vitro in Raji cells also suggests that glycosphingolipids play a major role in SEB interactions with these cells. The SEB binding assays showed that SEB bound non‐homogenously to the cells, a literature analysis, has suggested that this event was the result of SEB binding to the lipid rafts on the Raji cells. Further analysis is currently being carried out to identify ligands and targets for SEB on the cell surface.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: